Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03099356 · ClinicalTrials.gov registry record · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
A Phase 2 study of Metastatic Thyroid Cancer, sponsored by University of Michigan Rogel Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT03099356 is a Phase 2 study of Metastatic Thyroid Cancer that is actively recruiting participants, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 22 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03099356, a Phase 2 study of Metastatic Thyroid Cancer, is actively recruiting participants, sponsored by University of Michigan Rogel Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will be a non-randomized pilot trial using Cyclophosphamide and Sirolimus for the treatment of metastatic differentiated thyroid cancer. Patients will be treated with Sirolimus 4 mg, PO, days 1-28 as well as Cyclophosphamide 100 mg, PO, days 1-5 and 15-19. Cycle length will be 28 days. Patients will be monitored closely for toxicity and undergo imaging to evaluate efficacy once every 2 cycles.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Sirolimus
Study Locations (1)
Michigan
- University of Michigan Cancer Center - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2017-04-27 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03099356
The ClinicalTrials.gov registry entry for NCT03099356 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Thyroid Cancer appearing as the primary indexed condition, and to 2 interventions - of which Cyclophosphamide is the first listed.
NCT03099356 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT03099356 about?
NCT03099356 is a clinical study titled "Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer". This study will be a non-randomized pilot trial using Cyclophosphamide and Sirolimus for the treatment of metastatic differentiated thyroid cancer. Patients will be treated with Sirolimus 4 mg, PO, days 1-28 as well as Cyclophosphamide 100 mg, PO, days 1-5 and 15-19. Cycle length will be 28 days. Pa...
What is the current status of trial NCT03099356?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2017-04-27. Estimated completion is 2026-12.
What conditions does trial NCT03099356 study?
This clinical trial studies the following conditions: Metastatic Thyroid Cancer.
What interventions are being tested in trial NCT03099356?
The interventions under investigation include: Cyclophosphamide (DRUG), Sirolimus (DRUG).
Who is sponsoring clinical trial NCT03099356?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03099356 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Thyroid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.